Table 1.
Baseline Characteristics of Study Cohorts Before and After Weighting
| Variables | Unweighted Cohort | Weighted Cohort | ||||||
| DMAb | TPTD | SMD | DMAb | TPTD | SMD | |||
| n | 105 | 110 | ||||||
| Age, mean | 70.2 | 70.3 | 0.014 | 67.9 | 66.8 | 0.018 | ||
| Men, % | 7.6 | 4.5 | 0.129 | 5.4 | 5.8 | 0.015 | ||
| Race, white, % | 93.3 | 91.8 | 0.058 | 90.2 | 90.3 | 0.003 | ||
| BMI, mean | 24.1 | 22.8 | 0.287 | 23.2 | 23.9 | 0.049 | ||
| Smoking history, % | 23.8 | 10.9 | 0.346 | 12.2 | 12.0 | 0.010 | ||
| Obesity, % | 18.1 | 8.2 | 0.297 | 9.6 | 11.9 | 0.082 | ||
| Hyperthyroidism, % | 12.4 | 12.7 | 0.010 | 13.1 | 13.8 | 0.020 | ||
| Esophagus disease, % | 54.3 | 41.8 | 0.252 | 42.3 | 42.2 | 0.002 | ||
| Any malignancy, % | 36.2 | 11.8 | 0.595 | 16.8 | 17.0 | 0.005 | ||
| Renal disease, % | 29.5 | 9.1 | 0.536 | 10.6 | 11.4 | 0.024 | ||
| Diabetes, % | 24.8 | 14.5 | 0.259 | 17.0 | 16.6 | 0.012 | ||
| Hypertension, % | 64.8 | 57.3 | 0.154 | 57.6 | 57.0 | 0.012 | ||
| Hyperlipidemia, % | 78.1 | 69.1 | 0.205 | 70.8 | 72.4 | 0.034 | ||
| Cerebrovascular disease, % | 18.1 | 19.1 | 0.026 | 11.3 | 9.7 | 0.053 | ||
| Chronic pulmonary disease, % | 36.2 | 37.3 | 0.022 | 37.7 | 38.0 | 0.006 | ||
| Anemia, % | 48.6 | 37.3 | 0.230 | 43.9 | 45.3 | 0.028 | ||
| Hemiplegia or paraplegia, % | 21.9 | 14.5 | 0.192 | 13.7 | 14.2 | 0.015 | ||
| Rheumatoid arthritis, % | 11.4 | 13.6 | 0.067 | 5.9 | 5.5 | 0.014 | ||
| Osteoarthritis, % | 65.7 | 59.1 | 0.137 | 59.2 | 57.4 | 0.036 | ||
| Charlson comorbidity index, mean | 3.8 | 2.1 | 0.554 | 2.4 | 2.6 | 0.013 | ||
| Fractures | ||||||||
| Fragility fracture, % | 36.2 | 50.9 | 0.300 | 39.4 | 36.3 | 0.063 | ||
| BMD | ||||||||
| Lumbar spine, T-score | −2.3 | −2.7 | 0.396 | −2.4 | −2.3 | 0.061 | ||
| Total hip, T-score | −1.9 | −2.3 | 0.467 | −2.0 | −1.9 | 0.046 | ||
| Femoral neck, T-score | −2.3 | −2.5 | 0.372 | −2.3 | −2.2 | 0.057 | ||
| Lumbar spine, g/cm2 | 0.79 | 0.74 | 0.402 | 0.77 | 0.78 | 0.059 | ||
| Total hip, g/cm2 | 0.71 | 0.66 | 0.474 | 0.70 | 0.71 | 0.042 | ||
| Femoral neck, g/cm2 | 0.60 | 0.57 | 0.384 | 0.60 | 0.61 | 0.054 | ||
| Osteoporosis agents | ||||||||
| Prior oral BP duration, y | 5.9 | 6.8 | 0.199 | 6.6 | 6.7 | 0.008 | ||
| Prior intravenous BP duration, y | 1.4 | 0.8 | 0.271 | 1.1 | 1.2 | 0.045 | ||
| Glucocorticoids, % | 60.0 | 55.5 | 0.092 | 57.0 | 54.0 | 0.067 | ||
| HRT, % | 36.2 | 46.4 | 0.208 | 44.7 | 41.9 | 0.057 | ||
| Raloxifene, % | 9.5 | 13.6 | 0.129 | 11.9 | 11.3 | 0.016 | ||
| BP washout period, mo | 24.4 | 9.7 | 0.607 | 14.6 | 15.7 | 0.043 | ||
Abbreviation: BP, bisphosphonate; DMAb, denosumab; SMD, standardized mean difference; TPTD, teriparatide.